1356922-05-8
1356922-05-8
Chemical Structure
Bimagrumab (WT IgG1)
Synonym(s): Anti-ACVR2B Reference Antibody (WT IgG1); BYM338 (WT IgG1)
- CAS No.: 1356922-05-8
- Formula:N/A
- Molecular Weight:(142.78 kDa)
IUPAC Name: dimethyl (6E,13E)-5,12-dihydrocycloocta[1,2-b:5,6-b']diindole-6,13-dicarboxylate
SMILES: [Bimagrumab (WT IgG1)]
Biological Activity: Bimagrumab (Anti-ACVR2B Reference Antibody) (WT IgG1) is a human monoclonal antibody that retains a native wild-type Fc region and is capable of blocking the activin type II receptor (ActRII). Bimagrumab (WT IgG1) can be used in research concerning pathological muscle loss and weakness.[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bimagrumab (WT IgG1) | 99.50% | Bimagrumab (Anti-ACVR2B Reference Antibody) (WT IgG1) is a human monoclonal antibody that retains a native wild-type Fc region and is capable of blocking the activin type II receptor (ActRII). Bimagrumab (WT IgG1) can be used in research concerning pathological muscle loss and weakness.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. [Content Brief]
- [2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18. [Content Brief]
